More light on cancer and COVID-19 reciprocal interaction

被引：3

作者：

Brest, Patrick ^{[1
]}

Mograbi, Baharia ^{[1
]}

Hofman, Paul ^{[1
,2
]}

Milano, Gerard ^{[3
]}

机构：

[1] Univ Cote dAzur, CNRS, Ctr Antoine Lacassagne, IRCAN,Inserm,FHU OncoAge, F-06107 Nice, France

[2] Univ Cote dAzur, CHU Nice, Lab Clin & Expt Pathol, FHU OncoAge,Hosp Integrated Biobank BB 0033 00025, F-06001 Nice, France

[3] Univ Cote dAzur, Ctr Antoine Lacassagne, UPR7497, F-06100 Nice, France

来源：

BRITISH JOURNAL OF CANCER | 2021年 / 124卷 / 08期

关键词：

D O I：

10.1038/s41416-020-01246-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer patients are vulnerable to COVID-19 with consequences on treatment delays and on mortality rate. This Comment explores the interaction between COVID-19 and cancer with attention paid to the modulation by cancer treatments of both ADAM17 and TMPRSS2, the proteases which control ACE2 processing, the SARS-CoV-2 target.

引用

页码：1344 / 1345

页数：2

共 10 条

[1] Host Polymorphisms May Impact SARS-CoV-2 Infectivity [J].

Brest, Patrick ;

Refae, Sadal ;

Mograbi, Baharia ;

Hofman, Paul ;

Milano, Gerard .

TRENDS IN GENETICS, 2020, 36 (11) :813-815

[2] The metalloprotease ADAM17 in inflammation and cancer [J].

Duesterhoeft, Stefan ;

Lokau, Juliane ;

Garbers, Christoph .

PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (06)

[3] COVID-19 and cancer research [J].

Harris, Adrian L. .

BRITISH JOURNAL OF CANCER, 2020, 123 (05) :689-690

[4] TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome Coronavirus Spike Protein [J].

Heurich, Adeline ;

Hofmann-Winkler, Heike ;

Gierer, Stefanie ;

Liepold, Thomas ;

Jahn, Olaf ;

Poehlmann, Stefan .

JOURNAL OF VIROLOGY, 2014, 88 (02) :1293-1307

[5] Vandetanib and ADAM inhibitors synergistically attenuate the pathological migration of EBV-infected retinal pigment epithelial cells by regulating the VEGF-mediated MAPK pathway [J].

Kim, Daejin ;

Ko, Hyun-Suk ;

Park, Ga Bin ;

Hur, Dae Young ;

Kim, Yeong Seok ;

Yang, Jae Wook .

EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2017, 13 (04) :1415-1425

[6]

Lin BY, 1999, CANCER RES, V59, P4180

[7] Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N=4532) [J].

Montopoli, M. ;

Zumerle, S. ;

Vettor, R. ;

Rugge, M. ;

Zorzi, M. ;

Catapano, C., V ;

Carbone, G. M. ;

Cavalli, A. ;

Pagano, F. ;

Ragazzi, E. ;

Prayer-Galetti, T. ;

Alimonti, A. .

ANNALS OF ONCOLOGY, 2020, 31 (08) :1040-1045

[8] Determinants of COVID-19 disease severity in patients with cancer [J].

Robilotti, Elizabeth V. ;

Babady, N. Esther ;

Mead, Peter A. ;

Rolling, Thierry ;

Perez-Johnston, Rocio ;

Bernardes, Marilia ;

Bogler, Yael ;

Caldararo, Mario ;

Figueroa, Cesar J. ;

Glickman, Michael S. ;

Joanow, Alexa ;

Kaltsas, Anna ;

Lee, Yeon Joo ;

Lucca, Anabella ;

Mariano, Amanda ;

Morjaria, Sejal ;

Nawar, Tamara ;

Papanicolaou, Genovefa A. ;

Predmore, Jacqueline ;

Redelman-Sidi, Gil ;

Schmidt, Elizabeth ;

Seo, Susan K. ;

Sepkowitz, Kent ;

Shah, Monika K. ;

Wolchok, Jedd D. ;

Hohl, Tobias M. ;

Taur, Ying ;

Kamboj, Mini .

NATURE MEDICINE, 2020, 26 (08) :1218-+

[9] Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies [J].

Saini, Kamal S. ;

Tagliamento, Marco ;

Lambertini, Matteo ;

McNally, Richard ;

Romano, Marco ;

Leone, Manuela ;

Curigliano, Giuseppe ;

de Azambuja, Evandro .

EUROPEAN JOURNAL OF CANCER, 2020, 139 :43-50

[10] Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies [J].

Seyedpour, Simin ;

Khodaei, Behzad ;

Loghman, Amir H. ;

Seyedpour, Nasrin ;

Kisomi, Misagh F. ;

Balibegloo, Maryam ;

Nezamabadi, Sasan S. ;

Gholami, Bahareh ;

Saghazadeh, Amene ;

Rezaei, Nima .

JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (04) :2364-2392

← 1 →